Gene · 5892
Papers2,681
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
341 to 360 of 2,681
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay. | Front Oncol | 2023 | 37601688 | PubTator, text mining | PubMed |
| Metaplastic breast cancer and BRCA1: first strong evidence of a link. | Eur J Hum Genet | 2023 | 37592173 | PubTator, text mining | PubMed |
| Exome sequencing identifies breast cancer susceptibility genes and defines the contribution of coding variants to breast cancer risk. | Nat Genet | 2023 | 37592023 | PubTator, text mining | PubMed |
| Opportunistic genetic screening increases the diagnostic yield and is medically valuable for care of patients and their relatives with hereditary cancer. | J Med Genet | 2023 | 37591735 | PubTator, text mining | PubMed |
| Long-molecule scars of backup DNA repair in BRCA1- and BRCA2-deficient cancers. | Nature | 2023 | 37587346 | PubTator, text mining | PubMed |
| Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity. | Mol Oncol | 2023 | 37584393 | PubTator, text mining | PubMed |
| Linked-read based analysis of the medulloblastoma genome. | Front Oncol | 2023 | 37576901 | PubTator, text mining | PubMed |
| Clinical Impact of Polygenic Risk Score for Breast Cancer Risk Prediction in 382 Individuals with Hereditary Breast and Ovarian Cancer Syndrome. | Cancers (Basel) | 2023 | 37568754 | PubTator, text mining | PubMed |
| Potential pathogenic germline variant reporting from tumor comprehensive genomic profiling complements classic approaches to germline testing. | NPJ Precis Oncol | 2023 | 37568048 | PubTator, text mining | PubMed |
| A comprehensive analysis of Fanconi anemia genes in Chinese patients with high-risk hereditary breast cancer. | J Cancer Res Clin Oncol | 2023 | 37566130 | PubTator, text mining | PubMed |
| Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer. | BMC Cancer | 2023 | 37563628 | PubTator, text mining | PubMed |
| BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype. | EBioMedicine | 2023 | 37549632 | PubTator, text mining | PubMed |
| miR-34a-FOXP1 Loop in Ovarian Cancer. | ACS Omega | 2023 | 37546627 | PubTator, text mining | PubMed |
| Economic evaluations of predictive genetic testing: A scoping review. | PLoS One | 2023 | 37531363 | PubTator, text mining | PubMed |
| Personalized medicine with germline pathogenic variants: Importance of population- and region-wide evidence. | Cancer Sci | 2023 | 37530079 | PubTator, text mining | PubMed |
| Performance of clinical risk scores and prediction models to identify pathogenic germline variants in patients with advanced prostate cancer. | World J Urol | 2023 | 37528288 | PubTator, text mining | PubMed |
| The therapeutic targets of N6-methyladenosine (m6A) modifications on tumor radioresistance. | Discov Oncol | 2023 | 37522921 | PubTator, text mining | PubMed |
| The impact of an educational and information systems initiative on somatic BRCA testing rates in patients with high grade serous tubo-ovarian cancer in Western Australia. | Gynecol Oncol Rep | 2023 | 37520785 | PubTator, text mining | PubMed |
| Peptide-Based Vaccine against Breast Cancer: Recent Advances and Prospects. | Pharmaceuticals (Basel) | 2023 | 37513835 | PubTator, text mining | PubMed |
| DNA Damage Repair Pathways in Prostate Cancer: A Narrative Review of Molecular Mechanisms, Emerging Biomarkers and Therapeutic Targets in Precision Oncology. | Int J Mol Sci | 2023 | 37511177 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5892/papers?page=18